Vaccine Against Respiratory Syncytial Virus
Pontificia Universidad Catolica de Chile
Patricia Veronica Dauelsberg Tannenbaum
MetadatosMostrar el registro completo del ítem
Worldwide Infection With Rsv is the Leading Cause Of Lower Respiratory Tract Disease In Children Under Two Years Of Age. Rsv Can Cause Long-lasting Consequences Throughout Life Such As Asthma And Wheezing. As In Many Other Countries In Chile There Has Been a Dramatic Increase In the Number Of Respiratory Infections Due To Rsv During the Winter Season Which Has Led a Significant Increase In the Requirement Of Medical Attention And Hospitalizations. In Our Country These Annual Epidemics Cause An Excessive Saturation Of the Health System And Emergency Rooms Forcing the Conversion Of Beds To Handle the Increasing Flow Of Patients. Unfortunately There is Still No Vaccine Against This Virus And Currently Treatment For Rsv Infection is Poor Hindering the Recovery Of the Patient And Prolonging Recovery Time. In Addition the Disease Caused By This Virus Prevents the Establishment Of An Adequate Immune Memory And Therefore Re-infection is Extremely Frequent And Damaging. The Lack Of An Effective Vaccine Against This Virus is Mainly Due To the Complex Immune Response Induced After Infection With Rsv. As a Result Of a Previous Fondef Project Our Group Has Recently Developed a Safe And Immunogenic Formulation Based On Recombinant Bacille Of Calmette-guerin (bcg) Expressing Rsv Proteins. This Formulation Generates An Efficient Immune Response Against the Virus In Animal Models Of Viral Infection While Avoiding the Generation Of a Harmful Inflammatory Immune Response In the Lungs. These Studies Correspond To Experimental Tests In Pre-clinical Assays Which Show: 1. Safety Of the Formulation 2. Immunogenicity And 3. Its Ability To Induce a Protective Immune Response Against Infection With Rsv. Therefore This Vaccine Has Significant Potential For Being Considered As a Product To Be Evaluated In Humans To Prevent Infection And Disease Caused By Rsv. To Be Used In Humans This Vaccine Must Succeed a Series Of Phases In Healthy Volunteers As To Characterize the Formulation And Determine Its Safety And Immunogenicity. Currently We Are Completing the Production Of Cgmp (current Good Manufacturing Practice) Quality Doses Of Bcg-vrs Suitable For Injection In Humans And Studies Evaluating Pre-clinical Aspects Of This Formulation As Well As In Clinical Trials In Humans. In This Way We Can Move Forward On the Characterization Of This Vaccine Which Will Allow This Formulation To Reach Those Who Need It To Prevent Rsv Infection.